UBS reiterates Buy rating on Abbott Labs stock amid sustainable MedTech growth
PositiveFinancial Markets

UBS has reaffirmed its Buy rating on Abbott Labs stock, highlighting the company's sustainable growth in the MedTech sector. This is significant as it reflects confidence in Abbott's innovative products and market position, suggesting that investors can expect continued positive performance from the company.
— Curated by the World Pulse Now AI Editorial System